

Gene Therapy

Part I: Technologies & Markets

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech. Prof. Jain's 473 publications include 27 books (5 as editor + 22 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Prof. Jain has edited "Drug Delivery Systems" (2008, 2nd ed 2014) and "Drug Delivery to the Central Nervous System" (2010), both published by Humana/Springer. His other recent books include "Handbook of Nanomedicine" (Springer 2008; Chinese edition, Peking University Press 2011; 3rd ed Springer 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition. Chemical Industry Press 2016, 2nd ed Springer 2017) and "Handbook of Neuroprotection" (Springer 2011). Books that contain chapters on gene therapy include: Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011), Applications of Biotechnology in Neurology (Springer 2013), and Applications of Biotechnology in Oncology (Springer 2014). He has also edited "Applied Neurogenomics" (Springer in 2015).

A B O U T T H I S R E P O R T

Prof. Jain wrote the first commercial report on Gene Therapy in 1995, which was published by PJB Publication, London. This was followed by reports on Gene Therapy Vectors and Cancer Gene Therapy (1996). A report on Gene Therapy of Neurological Disorders was published by Decision Resources in 1997. In 1998, Prof. Jain wrote a Textbook of Gene Therapy, which was the first book on this subject to be translated into the Chinese language in 2000. A book on gene therapy companies was published in 2000 by John Wiley & Sons and continued to be updated online at Wiley's web site until 2003. In 2004, when the copyright reverted to Prof. Jain, it became part II of the Gene Therapy report. This report supercedes and updates all the previous books as well as reports.

November 2017
Copyright © 2017 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	21
1. Introduction	23
Definitions	23
Historical evolution of gene therapy	23
Relation of gene therapy to other biotechnologies.....	25
Molecular biological basics for gene therapy	26
Genome.....	26
DNA	26
RNA	27
<i>Alternative RNA splicing.....</i>	<i>28</i>
Genes.....	28
<i>Silent gene mutations.....</i>	<i>29</i>
Gene regulation	29
Gene expression	30
ENCODE	31
Chromosomes	31
Telomeres.....	32
Mitochondria	32
Proteins.....	33
2. Gene Therapy Technologies	35
Classification of gene therapy techniques.....	35
Ex vivo and in vivo gene therapy	36
Ex vivo gene therapy.....	36
In vivo gene therapy	37
Physical methods of gene transfer.....	37
Electroporation	37
Applications of electroporation	38
<i>Clinical applications of electroporation</i>	<i>39</i>
<i>Advantages of electroporation</i>	<i>40</i>
<i>Limitations of electroporation</i>	<i>40</i>
Hydrodynamic	40
Microinjection.....	41
Particle bombardment	41
Ultrasound-mediated transfection	43
Molecular vibration.....	43
Application of pulsed magnetic field and superparamagnetic nanoparticles	44
Gene transfection using laser irradiation	44
Photochemical transfection.....	45
Chemical methods of gene transfer	45
Gene repair and replacement.....	45
Gene repair by single-stranded oligonucleotides.....	46
History and current status of chimeraplasty	46
Genome editing.....	46
Gene editing by use of short synthetic oligonucleotides.....	46
Genome engineering by using TALENs	47
Targeted genome editing by artificial nucleases	47
Clinical applications of gene editing	47
Genome editing by using CRISPR system	48
<i>A method for generating genome-wide gRNA libraries for CRISPR.....</i>	<i>49</i>
<i>CRISPR for studying human embryogenesis</i>	<i>49</i>
<i>CRISPR for correction of a gene mutation in the human embryo</i>	<i>50</i>
<i>CRISPR system for creating animal models of human diseases.....</i>	<i>50</i>
<i>CRISPR/Cas9 technology for drug discovery</i>	<i>50</i>
<i>Expanding the range of Cas9s</i>	<i>51</i>
<i>Inducible CRISPR/Cas9 for multiple gene targeting</i>	<i>51</i>
<i>Photoactivatable CRISPR-Cas9.....</i>	<i>51</i>
<i>Protein delivery and genome editing.....</i>	<i>52</i>
<i>Potential clinical applications of CRISPR systems.....</i>	<i>52</i>
<i>PERV blockage by CRISPR to facilitate xenotransplantation</i>	<i>53</i>
<i>RNA editing with CRISPR.....</i>	<i>53</i>
<i>Clinical trial of CRISPR in human cancer.....</i>	<i>54</i>
<i>Complications and limitations of CRISPR/Cas9 technology.....</i>	<i>54</i>
<i>Companies developing CRISPR technology</i>	<i>55</i>
Base editing by protein engineering	55
mRNA gene therapy	56

Spliceosome mediated RNA trans-splicing	56
Vectors for gene therapy	57
Basic considerations	57
Use of genes as pharmaceuticals	57
The ideal vector for gene therapy	57
Viral vectors	58
<i>Adenovirus vectors</i>	59
<i>Adeno-associated virus vectors</i>	61
<i>Alphavirus vectors</i>	64
<i>Baculovirus vectors</i>	64
<i>Foamy virus vectors</i>	65
<i>Herpes simplex virus vectors</i>	65
<i>Lentiviral vectors</i>	67
<i>Multicistronic retroviral vectors</i>	68
<i>Retroviral vectors</i>	69
<i>Oncogenic potential of retroviral vectors</i>	70
<i>Quantification of viral vectors</i>	71
<i>Future of viral vectors</i>	71
<i>Companies using viral vectors</i>	71
Nonviral vectors for gene therapy	73
<i>Anionic lipid-DNA complexes</i>	73
<i>Cationic lipid-DNA complexes</i>	74
<i>Effects of shape of DNA molecules on delivery with nonviral vectors</i>	74
<i>Electrostatic modifications of surface to improve gene delivery</i>	75
<i>Liposomes for gene therapy</i>	75
<i>Liposome-nucleic acid complexes</i>	76
<i>Liposome-HVJ complex</i>	77
<i>Transposons DNA vectors</i>	77
<i>Polycation-DNA complexes (polyplexes)</i>	78
<i>Plasmid DNA vs minicircle DNA</i>	79
<i>Polymer vectors for gene therapy</i>	80
<i>Synthetic biology and DNA vectors</i>	80
<i>Synthetic peptide complexes</i>	81
<i>Future of nonviral vs viral vectors</i>	81
Nanobiotechnology for gene therapy	81
<i>Antisense nanoparticles</i>	82
<i>Dendrimers</i>	82
<i>Cochleates</i>	82
<i>Calcium phosphate nanoparticles as nonviral vectors</i>	83
<i>DNA nanoparticles as nonviral vectors</i>	83
<i>Gelatin nanoparticles for gene delivery</i>	83
<i>Lipid nanoparticles for nucleic acid delivery</i>	83
<i>Lipid nanoparticles for delivery of genome-editing proteins</i>	84
<i>Nanoparticles as nonviral vectors for gene therapy</i>	84
<i>Nanoparticles with virus-like function as gene therapy vectors</i>	85
<i>Nanoblastics for nucleic acid delivery</i>	85
<i>Nonionic polymeric micelles for oral gene delivery</i>	85
<i>Silica nanoparticles as a nonviral vector for gene delivery</i>	86
<i>Virus-like particles as nonviral vector</i>	86
Receptor-mediated endocytosis	86
Artificial viral vectors	87
Directed evolution of AAV to create efficient gene delivery vectors	88
Bacterial ghosts as DNA delivery systems	88
Bacteria plus nanoparticles for gene delivery into cells	89
Chromosome-based vectors for gene therapy	89
<i>Mammalian artificial chromosomes (MACs)</i>	90
<i>Human artificial chromosomes (HACs)</i>	90
<i>ΦC31 integrase system</i>	91
Companies using nonviral vectors	91
Concluding remarks about vectors	92
Cell-mediated gene therapy	93
Fibroblasts	93
Skeletal muscle cells	94
Vascular smooth muscle cells	95
Keratinocytes	95
Hepatocytes	95
Lymphocytes	95
<i>Regulating protein delivery by genetically encoded lymphocytes</i>	96
Implantation of microencapsulated genetically modified cells	96
Stem cell gene therapy	97
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	97

<i>Improving delivery of genes to stem cells</i>	97
<i>Lentiviral vectors for gene transfer to marrow stem cells</i>	98
<i>Use of mesenchymal stem cells for gene therapy</i>	98
<i>Microportation for transfection of MSCs</i>	98
<i>In utero gene therapy using stem cells</i>	98
<i>Gene delivery to stem cells by artificial chromosome expression</i>	99
<i>Linker based sperm-mediated gene transfer technology</i>	99
<i>Combination of gene therapy with therapeutic cloning</i>	99
<i>Expansion of transduced HSCs in vivo</i>	99
<i>The future of hematopoietic stem cell gene therapy</i>	100
Role of genetically modified bacteria in gene therapy	100
Routes of administration for gene therapy	101
Direct injection of naked DNA	101
Intramuscular injection.....	102
Intravenous DNA injection	102
Intraarterial delivery	102
Companies with gene delivery devices/technologies	102
Targeted gene therapy	103
Targeted integration.....	104
Bacteriophage integrase system for site-specific gene delivery	104
Controlled-release delivery of DNA	105
Controlled gene therapy	105
Controlled delivery of genetic material.....	105
Controlled induction of gene expression	106
Drug-inducible systems for control of gene expression.....	106
Timed activation of gene therapy by a circuit based on signaling network	107
Small molecules for post-transcriptional regulation of gene expression	107
Engineered zinc finger DNA binding proteins for gene correction	107
Light Activated Gene Therapy.....	108
Spatial control of gene expression via local hyperthermia.....	108
Companies with regulated /targeted gene therapy	108
Gene marking	109
Germline gene therapy	110
Potential applications of human germline genome modification	110
Pros and cons of human germline genome modification	110
Role of gene transfer in antibody therapy	112
Genetically engineered vaccines	112
DNA vaccines	112
<i>DNA inoculation technology</i>	113
<i>Methods for enhancing the potency of DNA vaccines</i>	113
<i>Advantages of DNA vaccines</i>	114
Vaccine vectors	114
Challenges and limitations of genetically engineered vaccines.....	115
RNA vaccines.....	115
<i>Nonviral delivery of self-amplifying RNA vaccine</i>	115
Vaccines based on reverse genetics.....	116
Technologies for gene suppression	116
Antisense oligonucleotides	116
Transcription factor decoys	117
Aptamers.....	117
Ribozymes	118
Peptide nucleic acid.....	118
<i>Intracellular delivery of PNAs</i>	118
Locked nucleic acid	119
<i>Zorro-LNA</i>	119
Gene silencing	119
Post-transcriptional gene silencing	120
Definitions and terminology of RNAi	120
RNAi mechanisms	120
Inhibition of gene expression by antigene RNA	121
RNAi gene therapy	121
microRNA gene therapy	122
Viral vectors for RNAi and miRNA gene therapy	122
Application of molecular diagnostic methods in gene therapy	123
Use of PCR to study biodistribution of gene therapy vector.....	124
PCR for verification of the transcription of DNA	124
In situ PCR for direct quantification of gene transfer into cells	124
Detection of retroviruses by reverse transcriptase (RT)-PCR.....	124
Confirmation of viral vector integration.....	124
Monitoring of gene expression	125
<i>Monitoring of gene expression by green fluorescent protein</i>	125

<i>Monitoring in vivo gene expression by molecular imaging</i>	125
<i>Advantages of gene therapy compared with protein therapy</i>	126
Formulation, transport and storage of materials for gene therapy	126

3. Clinical Applications of Gene Therapy	127
Introduction	127
Aging research	127
Bone and joint disorders	127
Bone fractures.....	127
Gene therapy for intervertebral disc degeneration.....	128
Spinal fusion	129
Osteogenesis imperfecta.....	129
Rheumatoid arthritis.....	130
<i>Local or systemic treatment</i>	130
<i>In vivo or ex vivo gene therapy of RA</i>	130
<i>Clinical trials of gene therapy for rheumatoid arthritis</i>	131
Gene therapy for osteoarthritis.....	132
Sports injuries.....	134
<i>Repair of articular cartilage defects</i>	134
Regeneration and replacement of bone by gene therapy	135
Bacterial infections	135
Antisense approach to bacterial infections	136
Dentistry	136
Tissue engineering in dental implant defects	136
Endocrine and metabolic disorders	137
Introduction	137
Gene therapy of obesity.....	137
<i>AAV vector-mediated delivery of GDNF for obesity</i>	137
<i>Oligopeptide for targeted nonviral gene delivery to adipocytes</i>	137
<i>Viral vector-mediated leptin gene therapy</i>	138
Diabetes mellitus	138
Methods of gene therapy of diabetes mellitus	139
<i>Viral vector-mediated gene transfer in diabetes</i>	140
<i>Gene delivery with ultrasonic microbubble destruction technology</i>	140
<i>Genetically engineered cells for diabetes mellitus</i>	141
<i>Genetically altered liver cells</i>	141
<i>Genetically modified stem cells</i>	141
<i>Genetically engineered dendritic cells</i>	142
<i>Glucokinase and insulin co-expression</i>	142
<i>Leptin gene therapy</i>	142
<i>Concluding remarks about cell and gene therapy of diabetes</i>	142
Gene therapy of growth-hormone deficiency	143
Gastrointestinal disorders	144
Introduction	144
Methods of gene transfer to the gastrointestinal tract.....	144
<i>Direct delivery of genes</i>	144
<i>Naked plasmid DNA into the submucosa</i>	145
<i>Viral vectors</i>	145
<i>Receptor-mediated endocytosis</i>	145
Indications for gastrointestinal gene therapy	145
<i>Gene therapy for inflammatory disorders of the bowel</i>	146
Gene transfer to the salivary glands.....	147
<i>Potential clinical applications of salivary gene therapy</i>	147
Hematology	148
Hemophilias	148
<i>Gene therapy of hemophilia</i>	148
<i>Hemophilia A</i>	149
<i>Hemophilia B</i>	150
<i>Concluding remarks about gene therapy of hemophilias</i>	151
Hemoglobinopathies.....	152
<i>Gene therapy for β-thalassemia</i>	152
<i>Gene therapy for sickle cell disease</i>	154
<i>Gene therapy and RNAi for SCD based on stem cells</i>	154
<i>Gene editing in sickle cell disease</i>	155
<i>Gene editing using ZFN as treatment for both SCD and β-thalassemia</i>	155
<i>Gene editing using CRISPR-Cas9 for both SCD and β-thalassemia</i>	155
<i>Gene therapy of Fanconi's anemia</i>	155
Acquired hematopoietic disorders.....	156
<i>Chronic acquired anemias</i>	156
<i>Neutropenia</i>	157
<i>Thrombocytopenia</i>	157

Concluding remarks about gene therapy of hemoglobinopathies	158
Companies involved in gene therapy of hematological disorders	158
In utero/fetal gene therapy.....	159
Fetal gene transfer techniques.....	159
Animal models of fetal gene therapy	160
Potential applications of fetal gene therapy	160
<i>Fetal gene therapy for cystic fibrosis</i>	<i>161</i>
<i>Fetal intestinal gene therapy</i>	<i>161</i>
<i>Gene therapy for fetal growth restriction.....</i>	<i>161</i>
Hearing disorders	162
Potential of gene therapy	162
Vectors for gene therapy of hearing disorders.....	163
Auditory hair cell replacement and hearing improvement by gene therapy	163
Kidney diseases	164
End-stage renal disease.....	164
Methods of gene delivery to the kidney.....	164
<i>Gene transfer into kidney by adenoviral vectors.....</i>	<i>165</i>
<i>Non-viral gene transfer to the kidneys.....</i>	<i>165</i>
<i>Gene transfer into the glomerulus by HVJ-liposome.....</i>	<i>165</i>
<i>Bone marrow stem cells for renal disease</i>	<i>165</i>
<i>Mesangial cell therapy</i>	<i>166</i>
<i>Liposome-mediated gene transfer into the tubules</i>	<i>166</i>
<i>Gene transfer to tubules with cationic polymer polyethylenimine.....</i>	<i>166</i>
Gene therapy in animal experimental models of renal disease	167
Genetic manipulations of the embryonic kidney	167
Antisense intervention in glomerulonephritis	167
Gene therapy for renal fibrosis	168
Use of genetically engineered cells for uremia due to renal failure.....	168
Concluding remarks	169
Liver disorders.....	169
Techniques of gene delivery to liver	170
<i>Direct injection of DNA into liver</i>	<i>170</i>
<i>Local gene delivery by isolated organ perfusion</i>	<i>170</i>
<i>Liposome-mediated direct gene transfer</i>	<i>170</i>
<i>Retroviral vector for gene transfer to liver.....</i>	<i>170</i>
<i>Adenoviral vectors for gene transfer to liver.....</i>	<i>171</i>
<i>Receptor-mediated approach.....</i>	<i>171</i>
Cell therapy for liver disorders.....	171
<i>Transplantation of genetically modified hepatocytes</i>	<i>172</i>
<i>Genetically modified hematopoietic stem cells</i>	<i>172</i>
<i>Gene therapy by ex vivo transduced liver progenitor cells</i>	<i>172</i>
Gene therapy of genetic diseases affecting the liver	173
<i>Crigler-Najjar syndrome</i>	<i>173</i>
<i>Hereditary tyrosinemia type I (HT1)</i>	<i>173</i>
<i>Hereditary tyrosinemia type 3</i>	<i>174</i>
Gene therapy of acquired diseases affecting the liver	174
<i>Cirrhosis of liver</i>	<i>174</i>
Ophthalmic disorders.....	174
Introduction to gene therapy of ophthalmic disorders	174
Methods of gene therapy for ophthalmic disorders	175
<i>Delivery of gene therapy by intravitreal injection</i>	<i>176</i>
<i>DNA nanoparticles for nonviral gene transfer to the eye.....</i>	<i>177</i>
<i>Optogenetic gene therapy for blindness due to retinal degeneration</i>	<i>177</i>
Age-related macular degeneration	178
Inherited disorders of optic nerve affecting vision	179
<i>Leber hereditary optic neuropathy.....</i>	<i>179</i>
Inherited retinal degenerations.....	180
<i>Choroideremia.....</i>	<i>181</i>
<i>Leber congenital amaurosis.....</i>	<i>182</i>
<i>Retinitis pigmentosa.....</i>	<i>184</i>
<i>Stargardt disease.....</i>	<i>185</i>
Other inherited disorders affecting vision	185
<i>Color blindness</i>	<i>185</i>
<i>Usher syndrome</i>	<i>186</i>
<i>X-linked retinoschisis.....</i>	<i>187</i>
Diabetic retinopathy	188
Future prospects of gene therapy of inherited retinal degenerations	188
<i>Combining cell and gene therapies for retinal disorders.....</i>	<i>188</i>
Prevention of complications associated with eye surgery	189
<i>Prevention of proliferative retinopathy by gene therapy</i>	<i>189</i>
<i>Posterior capsule opacification after cataract surgery.....</i>	<i>189</i>

Autoimmune uveitis	189
Retinal ischemic injury.....	189
Corneal disorders.....	190
Glaucoma	190
Corneal scarring	191
Companies developing gene therapy for eye disorders.....	191
Organ transplantation.....	191
Introduction	191
DNA vaccines for transplantation	192
Gene therapy for prolonging allograft survival	192
<i>Genetically modified Tregs expressing CAR for preventing GVHD</i>	192
Gene therapy in lung transplantation.....	193
Role of gene therapy in liver transplantation	193
Gene therapy in kidney transplantation.....	193
Veto cells and transplant tolerance.....	194
Pulmonary disorders.....	194
Techniques of gene delivery to the lungs	195
<i>Adenoviral vectors</i>	195
<i>Nonviral vectors</i>	196
<i>Aerosolization as an aid to gene transfer to lungs.</i>	196
Cystic fibrosis.....	197
<i>Genetics and clinical features</i>	197
<i>Gene therapy for CF</i>	197
<i>CFTR gene transfer in CF</i>	197
<i>Concluding remarks about gene therapy of CF</i>	199
Miscellaneous pulmonary disorders	199
<i>Gene therapy for pulmonary arterial hypertension</i>	199
<i>Gene therapy for bleomycin-induced pulmonary fibrosis</i>	200
<i>Gene therapy of emphysema due to α1-antitrypsin deficiency</i>	200
<i>Gene therapy for asthma</i>	201
<i>Gene therapy for adult respiratory distress syndrome</i>	201
<i>Gene therapy for lung injury</i>	201
<i>Gene therapy for bronchopulmonary dysplasia</i>	202
Concluding remarks about gene therapy of lungs.....	202
Companies involved in pulmonary gene therapy	203
Skin and soft tissue disorders.....	204
Gene transfer to the skin	204
<i>Electroporation for transdermal delivery of plasmid DNA</i>	204
<i>Electroporation for transdermal delivery of DNA vaccines</i>	205
<i>Liposomes for transdermal gene delivery</i>	205
<i>Ultrasound and topical gene therapy</i>	205
Gene therapy in skin disorders	205
<i>Gene therapy of hair loss</i>	206
<i>Gene therapy for epidermolysis bullosa</i>	206
<i>Gene therapy for xeroderma pigmentosa</i>	207
<i>Gene therapy for lamellar ichthyosis</i>	207
<i>Gene therapy for epidermolysis bullosa</i>	208
Gene transfer techniques for wound healing	208
Urogenital disorders	209
Gene therapy for urinary tract dysfunction	209
Gene therapy for erectile dysfunction	209
<i>NOS gene transfer for erectile dysfunction</i>	209
<i>Clinical trial of hMaxi-K Gene transfer in erectile dysfunction</i>	210
<i>Gene therapy for erectile dysfunction due to nerve injury</i>	210
<i>Concluding remarks on gene therapy for erectile dysfunction</i>	210
Veterinary gene therapy	211
Gene therapy for mucopolysaccharidosis VII in dogs	211
Gene therapy to increase disease resistance.....	211
Gene therapy for infections	212
Gene therapy for chronic anemia	212
Gene therapy for endocrine disorders	213
Gene therapy for arthritis.....	213
Cancer gene therapy	213
<i>Brain tumors in cats and dogs</i>	214
<i>Breast cancer in dogs</i>	214
<i>Canine hemangiosarcoma</i>	215
<i>Canine melanoma</i>	215
<i>Canine soft tissue sarcoma</i>	215
Melanoma in horses	216
4. Gene Therapy of Genetic Disorders.....	217

Introduction	217
Primary immunodeficiency disorders.....	218
Severe combined immune deficiency	219
Chronic granulomatous disease	222
Wiskott-Aldrich syndrome	222
Purine nucleoside phosphorylase deficiency	223
Major histocompatibility class II deficiency	223
Future prospects of gene therapy of inherited immunodeficiencies	224
Metabolic disorders.....	224
Alpha1-antitrypsin deficiency.....	225
<i>AAV mediated gene therapy for a1-antitrypsin deficiency.....</i>	<i>225</i>
<i>iPSCs for targeted gene correction of a1-antitrypsin deficiency</i>	<i>226</i>
Adrenoleukodystrophy	227
Canavan disease.....	228
Lesch-Nyhan syndrome	229
Lipoprotein lipase deficiency.....	229
<i>Alipogene tiparvovec</i>	<i>229</i>
Ornithine transcarbamylase deficiency.....	230
<i>Gene therapy for OTCD.....</i>	<i>230</i>
<i>AAV-mediated gene editing for OTCD using CRISPR-Cas9</i>	<i>231</i>
Phenylketonuria.....	231
Porphyrias	232
Tetrahydrobiopterin deficiency.....	233
Lysosomal storage disorders.	233
Batten disease.....	234
Fabry's disease.....	235
Farber's disease.....	235
Gaucher disease	235
<i>Animals models of Gaucher's disease.....</i>	<i>236</i>
<i>Gene therapy of Gaucher's disease.....</i>	<i>236</i>
Hunter syndrome.....	237
Krabbe's disease	237
Metachromatic leukodystrophy	238
Mucopolysaccharidosis type 1 (Hurler syndrome).....	239
Niemann-Pick type A disease.....	239
Pompe disease	239
Sanfilippo A syndrome.....	240
Sly syndrome	241
Tay-Sachs disease	241
Future prospects of gene therapy of lysosomal storage disorders	241
Trinucleotide repeat disorders	242
Muscular dystrophies.....	242
Duchenne muscular dystrophy (DMD).....	242
<i>Animal models for gene therapy of DMD</i>	<i>243</i>
<i>Antisense approaches to DMD.....</i>	<i>243</i>
<i>Exon-skipping for DMD</i>	<i>243</i>
<i>Galgt2 gene therapy.....</i>	<i>245</i>
<i>Liposome-mediated gene transfer</i>	<i>245</i>
<i>Microdystrophin gene therapy.....</i>	<i>245</i>
<i>Myoblast-based gene transfer in DMD.....</i>	<i>245</i>
<i>Plasmid-mediated gene therapy.....</i>	<i>246</i>
<i>Purinoreceptor P2RX7 ablation.....</i>	<i>246</i>
<i>Post-transcriptional modulation of gene expression in DMD</i>	<i>247</i>
<i>Repair/Editing of dystrophin gene</i>	<i>247</i>
<i>Routes of administration of gene therapy in DMD.....</i>	<i>249</i>
<i>Types of dystrophin constructs</i>	<i>250</i>
<i>Viral vectors for DMD</i>	<i>250</i>
<i>Conclusions and future of gene therapy of DMD</i>	<i>251</i>
Limb-girdle muscular dystrophy.....	252
Myotonic dystrophy	253
Spinal muscular atrophy	253
<i>Gene therapy for SMA</i>	<i>253</i>
<i>Antisense therapy of SMA</i>	<i>254</i>
X-linked myotubular myopathy (XLMTM).....	254
Hereditary neuropathies	254
Charcot-Marie-Tooth disease	254
Hereditary axonal neuropathies of the peripheral nerves.....	255
Gene therapy of mitochondrial disorders	255
Techniques for mitochondrial replacement therapy.....	256
Status of mitochondrial replacement and transfer therapies	257
Companies involved in gene therapy of genetic disorders	258

5. Gene Therapy of Cancer	259
Strategies for cancer gene therapy	259
Direct gene delivery to the tumor	260
Injection into tumor	260
<i>Direct injection of adenoviral vectors</i>	260
<i>Direct injection of a plasmid DNA-liposome complex</i>	261
<i>A polymer approach to local gene therapy for cancer</i>	261
Electroporation for cancer gene therapy	261
Control of gene expression in tumor by local heat	262
Radiation-guided gene therapy of cancer	262
Radioprotective gene therapy	262
Nanoparticles to facilitate combination of hyperthermia and gene therapy	263
Cell-based cancer gene therapy	263
Adoptive cell therapy	263
Cytokine gene therapy	264
Genetic modification of human hematopoietic stem cells	267
Immunogene therapy	267
Cancer vaccines	268
Genetically modified cancer cell vaccines	268
<i>GVAX cancer vaccines</i>	268
<i>Genetically modified dendritic cells</i>	269
Nucleic acid-based cancer vaccines	269
<i>DNA cancer vaccines</i>	269
<i>RNA vaccines</i>	269
Viral vector-based cancer vaccines	270
<i>Intradermal delivery of cancer vaccines by Ad vectors</i>	270
Future of cancer vaccines	271
Companies involved in nucleic acid-based cancer vaccines	271
Monoclonal antibody gene transfer for cancer	272
Transfer and expression of intracellular adhesion-1 molecules	272
Other gene therapy techniques for immunotherapy of cancer	272
Chemokines	273
CRISPR for immunogene therapy	273
Engineered viruses as anticancer immunotherapy vectors	274
Fas (Apo-1)	274
Major Histocompatibility Complex (MHC) Class I	274
IGF (Insulin-Like Growth Factor)	275
Inhibition of immunosuppressive function in cancer	275
Delivery of toxic genes to tumor cells for eradication	275
Gene-directed enzyme prodrug therapy	275
Combination of gene therapy with radiotherapy	276
Correction of genetic defects in cancer cells	276
Targeted gene therapy for cancer	277
Antiangiogenic therapy for cancer	277
Bacteria as novel anticancer gene vectors	278
Cancer-specific gene expression	278
Cancer-specific transcription	278
Delivery of retroviral particles hitchhiking on T cells	279
Electrogene and electrochemotherapy	279
Epidermal growth factor-mediated DNA delivery	279
Gene expression in hypoxic tumor cells	280
Genetically modified T cells for targeting tumors	280
<i>Chimeric antigen receptor T cells</i>	281
Genetically engineered stem cells for targeting tumors	283
Hematopoietic stem cells for targeted cancer gene therapy	284
Immunolipoplex for delivery of p53 gene	284
Nanomagnets for targeted cell-based cancer gene therapy	285
Nanoparticles for targeted site-specific delivery of anticancer genes	285
Targeted cancer therapy using a dendrimer-based synthetic vector	285
Tumor-targeted gene therapy by receptor-mediated endocytosis	286
Virus-mediated oncolysis	286
<i>Cytokine-induced killer cells for delivery of an oncolytic virus</i>	286
<i>Monitoring of viral-mediated oncolysis by PET</i>	287
<i>Oncolytic adenoviruses</i>	287
<i>Oncolytic HSV</i>	288
<i>Oncolytic measles viruses</i>	289
<i>Oncolytic vaccinia virus</i>	289
<i>Oncolytic vesicular stomatitis virus</i>	290
<i>Targeted cancer treatments based on oncolytic viruses</i>	290
<i>Concluding remarks on oncolytic gene therapy</i>	290
<i>Companies developing oncolytic viruses</i>	291

Apoptotic approach to improve cancer gene therapy	292
Tumor suppressor gene therapy	292
P53 gene therapy.....	292
BRIT1 gene therapy	293
Nitric oxide-based cancer gene therapy	293
Anticancer effect of nitric oxide synthase	293
Gene therapy for radiosensitization of cancer	293
Gene therapy of cancer of selected organs	293
Gene therapy for bladder cancer.....	294
Gene therapy for glioblastoma multiforme.	294
<i>Adenoviral vectors for treatment of brain tumors</i>	295
<i>Antiangiogenic gene therapy</i>	296
<i>Autophagy induced by conditionally replicating adenoviruses</i>	296
<i>Baculovirus vector for diphtheria toxin gene therapy</i>	297
<i>Cerepro® (sitimagene ceradenovec)</i>	297
<i>Gene therapy targeting hepatocyte growth factor</i>	297
<i>Genetically engineered MSCs for gene delivery to intracranial gliomas</i>	298
<i>Intravenous gene delivery with nanoparticles into brain tumors</i>	298
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i>	298
<i>Olig2 targeting to hinder growth of treatment-resistant glioblastomas</i>	299
<i>RNAi gene therapy of brain cancer</i>	299
<i>Targeting normal brain cells with an AAV vector encoding interferon-β</i>	299
<i>Viral oncolysis of glioblastoma multiforme</i>	300
Gene therapy for breast cancer.....	301
<i>Gene vaccine for breast cancer</i>	302
<i>Recombinant adenoviral ErbB-2/neu vaccine</i>	302
Gene Therapy for ovarian cancer	303
Gene therapy for malignant melanoma	303
<i>Immunogene therapy</i>	304
<i>Nonviral immunogene therapy for malignant melanoma</i>	305
<i>Oncogene targeted therapy</i>	305
<i>Targeted gene therapy for malignant melanoma</i>	305
Gene therapy of lung cancer.....	306
<i>Intravenous nanoparticle formulation for delivery of FUS1 gene</i>	306
<i>Aerosol gene delivery for lung cancer</i>	306
Gene therapy for cancer of prostate	307
<i>Experimental studies</i>	307
<i>Nanoparticle-based gene therapy for prostate cancer</i>	307
<i>Tumor suppressor gene therapy in prostate cancer</i>	307
<i>Vaccines for prostate cancer</i>	308
<i>Viral oncolysis for prostate cancer</i>	308
<i>Clinical trials of gene therapy for prostate cancer</i>	308
Gene therapy of head and neck cancer	309
<i>Adenoviral vector based P53 gene therapy</i>	309
<i>Gene therapy as adjunct to 5-FU for nasopharyngeal carcinoma</i>	309
Gene therapy of pancreatic tumors	310
<i>Pancreatic neuroendocrine tumors</i>	310
<i>Pancreatic ductal adenocarcinoma</i>	310
<i>Correction of altered genes</i>	311
<i>Targeted gene therapy</i>	311
<i>Targeting in pancreatic adenocarcinoma with cell surface antigens</i>	311
<i>Targeted Expression of BikDD gene</i>	312
<i>Viral oncolysis in pancreatic cancer</i>	312
<i>Concluding remarks on gene therapy of pancreatic cancer</i>	312
Gene therapy of renal cancer.....	312
<i>Viral oncolytic therapy for renal cancer</i>	312
Gene therapy of hematological malignancies	313
<i>Genetically engineered T lymphocytes</i>	313
Cancer gene therapy companies	313
6. Gene Therapy of Neurological Disorders	317
Indications	317
Gene transfer techniques for the nervous system.....	318
Methods of gene transfer to the nervous system.....	318
Ideal vector for gene therapy of neurological disorders	318
Promoters of gene transfer.....	318
Lentivirus-mediated gene transfer to the CNS	319
AAV vector mediated gene therapy for neurogenetic disorders.....	319
Gene transfer to the CNS using recombinant SV40-derived vectors	320
Routes of delivery of genes to the CNS	320
<i>Direct injection into CNS</i>	320

<i>Introduction of the genes into cerebral circulation</i>	321
<i>Introduction of genes into cerebrospinal fluid</i>	321
<i>Intravenous administration of vectors</i>	322
Delivery of gene therapy to the peripheral nervous system	322
Cell-mediated gene therapy of neurological disorders	322
<i>Neuronal cells</i>	322
<i>Neural stem cells and progenitor cells</i>	322
<i>Astrocytes</i>	323
<i>Cerebral endothelial cells</i>	323
<i>Implantation of genetically modified encapsulated cells into the brain</i>	323
Gene transfer for neuromodulation.....	323
Gene therapy of neurodegenerative disorders	324
Gene therapy for Parkinson disease.....	324
Rationale	325
<i>Techniques of gene therapy for PD</i>	325
<i>Augmenting CNS glucocerebrosidase activity</i>	328
<i>Delivery of neurotrophic factors by gene therapy</i>	329
<i>Delivery of parkin gene</i>	329
<i>Introduction of functional genes into the brain of patients with PD</i>	329
<i>Nanoparticle-based gene therapy for PD</i>	330
<i>Mitochondrial gene therapy for PD</i>	330
<i>RNAi approach to PD</i>	330
<i>Prospects of gene therapy for PD</i>	331
<i>Concluding remarks about gene therapy of PD</i>	332
<i>Companies developing gene therapy for PD</i>	332
Gene therapy for Alzheimer disease	332
Rationale	332
<i>NGF gene therapy for AD</i>	333
<i>FGF2 gene transfer in AD</i>	334
<i>Nepriylsin gene therapy</i>	334
<i>Targeting plasminogen activator inhibitor type-1 gene</i>	335
<i>Viral gene transfer of APPs_a for rescuing synaptic failure in AD</i>	335
<i>Gene vaccination</i>	335
<i>Combination of gene therapy with other treatments for AD</i>	336
Gene therapy of Huntington disease.....	336
<i>Encapsulated genetically engineered cellular implants</i>	336
<i>Viral vector mediated administration of neurotrophic factors</i>	336
<i>RNAi gene therapy</i>	337
Gene therapy of amyotrophic lateral sclerosis.....	337
Rationale	337
<i>Technique of gene therapy of ALS</i>	337
<i>Other approaches to gene therapy of ALS</i>	338
Gene therapy of cerebrovascular diseases	338
Preclinical research in gene therapy for cerebrovascular disease	339
Animal models of stroke relevant to gene therapy.....	339
<i>Transgenic mice as models for stroke</i>	339
<i>Animal models for gene therapy of arteriovenous malformations</i>	340
Gene transfer to cerebral blood vessels	340
Gene therapy for vasospasm following subarachnoid hemorrhage	341
<i>NOS gene therapy for cerebral vasospasm</i>	342
Gene therapy for stroke.....	342
<i>Gene therapy for stroke using neurotrophic factors</i>	343
<i>Gene therapy of strokes with a genetic component</i>	344
<i>Gene therapy for intracranial aneurysms</i>	344
<i>RNAi-based gene silencing for neuroprotection in cerebral ischemia</i>	344
Concluding remarks about gene therapy for stroke.....	344
Gene therapy of injuries to the nervous system.....	345
Traumatic brain injury	345
Spinal cord injury.....	345
Peripheral nerve injuries	346
Gene therapy of epilepsy	346
Gene therapy for control of seizures	347
Gene therapy for neuroprotection in epilepsy	348
Gene therapy for genetic forms of epilepsy	348
Gene therapy for multiple sclerosis	349
Gene therapy for impairment of special senses	349
Gene therapy for hearing loss.....	349
Gene therapy for olfactory impairment	350
Gene therapy for relief of pain.....	351
Rationale of gene therapy for pain	351
Vectors for gene therapy of pain	351

Methods of gene delivery for pain	351
<i>Endogenous analgesic production for cranial neuralgias</i>	352
<i>Gene delivery by intrathecal route</i>	352
<i>Gene transfer for delivery of analgesics to the spinal nerve roots</i>	353
<i>Gene therapy of peripheral neuropathic pain</i>	354
<i>Gene transfer by injections into the brain substance</i>	355
Targets for gene therapy of pain	355
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i>	355
<i>Gene therapy for producing enkephalin to block pain signals</i>	355
<i>Targeting nuclear factor-κB</i>	356
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	356
Potential applications of gene therapy for management of pain	357
Concluding remarks on gene therapy for pain	357
Gene therapy for psychiatric disorders	358
Gene therapy for depression	358
Gene therapy for enhancing cognition after stress	359
Gene therapy against fear disorders	359
Companies involved in gene therapy of neurological disorders	359

7. Gene Therapy of Cardiovascular Disorders 361

Introduction	361
Techniques of gene transfer to the cardiovascular system	361
Direct plasmid injection into the myocardium	362
Catheter-based systems for vector delivery	362
Ultrasound microbubbles for cardiovascular gene delivery	363
Vectors for cardiovascular gene therapy	363
<i>AAV vectors for therapeutic delivery to the heart</i>	363
<i>Adenoviral vectors for cardiovascular diseases</i>	364
<i>Molecular cardiac surgery with recirculating delivery of AAV vectors</i>	364
<i>Plasmid DNA-based delivery in cardiovascular disorders</i>	364
Gene therapy for counteracting hypoxia in myocardial ischemia	364
Therapeutic angiogenesis vs vascular growth factor therapy	365
Gene painting for delivery of targeted gene therapy to the heart	365
Gene delivery to vascular endothelium	366
Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles	366
Vascular stents for gene delivery	367
Gene therapy for genetic cardiovascular disorders	367
Catecholaminergic polymorphic ventricular tachycardia	367
Genetic disorders predisposing to atherosclerosis	368
Familial hypercholesterolemia	369
Apolipoprotein E deficiency	370
Hypertension	371
Genetic factors for myocardial infarction	371
Acquired cardiovascular diseases	372
Coronary artery disease with angina pectoris	372
<i>Ad5FGF-4</i>	372
Gene therapy for improving long-term CABG patency rates	373
Ischemic heart disease with myocardial infarction	373
<i>Gene therapy and angiogenesis in ischemic heart disease</i>	374
<i>Induction of angiogenesis in myocardium by HEXIM1 re-expression</i>	374
<i>Myocardial repair with IGF-1 therapy</i>	375
<i>Metalloproteinase-2 inhibitor gene therapy</i>	375
<i>miRNA gene therapy for ischemic heart disease</i>	376
Congestive heart failure	376
<i>Rationale of gene therapy in CHF</i>	376
<i>AAV-mediated gene transfer for CHF</i>	377
<i>AngioCell gene therapy for CHF</i>	377
<i>β-ARKct gene therapy</i>	378
<i>Elevating cardiac dATP by gene therapy to improve cardiac function</i>	378
<i>Elevating cardiac adenylyl cyclase type 6 to improve cardiac function</i>	379
<i>Intracoronary adenovirus-mediated gene therapy for CHF</i>	380
<i>nNOS gene transfer in CHF</i>	380
Cardiomyopathies	380
Cardiac conduction disturbances	381
<i>Gene transfer approaches for biological pacemakers</i>	381
<i>Genetically engineered biological pacemakers</i>	382
Gene therapy and heart transplantation	382
Hyperlipidemia and hypercholesterolemia	383
<i>Antisense approach to hypertriglyceridemia</i>	383
<i>Cholesterol reduction by genetic engineering of PCSK9 gene</i>	383
<i>Inactivating variants in ANGPTL4 for lowering circulating triglycerides</i>	383

Peripheral arterial disease	384
Incidence and clinical features	384
Current management	384
Gene therapy for peripheral arterial disease	384
<i>Angiogenesis by gene therapy</i>	384
<i>HIF-1α gene therapy for peripheral arterial disease</i>	385
<i>HGF gene therapy for peripheral arterial disease</i>	385
Prevention of restenosis after angioplasty	386
<i>Antisense approaches</i>	386
<i>Gene therapy to prevent restenosis after angioplasty</i>	387
<i>hTIMP-1 gene therapy to prevent intimal hyperplasia</i>	388
<i>miRNA-based gene therapy for restenosis</i>	388
<i>NOS gene therapy for restenosis</i>	389
<i>Techniques of gene therapy for restenosis</i>	389
Maintaining vascular patency after surgery	390
Companies involved in gene therapy of cardiovascular diseases	390
Future of gene therapy of cardiovascular disorders.....	391
8. Gene therapy of viral infections	393
Introduction	393
Acquired Immunodeficiency Syndrome (AIDS)	393
Current management of AIDS.....	393
Gene therapy strategies in HIV/AIDS.....	394
<i>HIV/AIDS vaccines</i>	394
<i>Insertion of protective genes into target cells</i>	395
Cell/gene therapies for HIV/AIDS.....	396
<i>Transplantation of genetically modified T cells</i>	396
<i>Transplantation of genetically modified hematopoietic cells</i>	397
<i>Anti-HIV ribozyme delivered in hematopoietic progenitor cells</i>	398
Inhibition of HIV-1 replication by lentiviral vectors	398
<i>VRX496-T</i>	398
Intracellular immunization.....	399
Engineered cellular proteins such as soluble CD4s.....	399
Intracellular antibodies	399
Anti-rev single chain antibody fragment.....	400
Use of genes to chemosensitize HIV-1 infected cells.....	400
Autocrine interferon (INF)- β production by somatic cell gene therapy	400
Antisense approaches to AIDS	400
<i>RNA decoys</i>	400
<i>Antisense oligodeoxynucleotides</i>	401
<i>RNA decoys</i>	401
<i>Ribozymes</i>	401
RNAi applications in HIV/AIDS	402
<i>siRNA-directed inhibition of HIV-1 infection</i>	402
<i>Role of the nef gene during HIV-1 infection and RNAi</i>	403
<i>Bispecific siRNA constructs</i>	403
<i>Targeting CXCR4 with siRNAs</i>	403
<i>Targeting CCR5 with siRNAs</i>	404
Companies involved in developing gene therapy for HIV/AIDS	404
Conclusions regarding gene therapy of HIV/AIDS.....	405
Genetic vaccines for other viral infections	406
Cytomegalic virus infections	406
Viral hepatitis	406
<i>Vaccine for hepatitis B</i>	407
<i>Vaccine for hepatitis C</i>	407
<i>Gene therapy for hepatitis C</i>	407
Vaccine for herpes simplex virus.....	407
DNA vaccine against rabies	408
DNA vaccine for Ebola	408
Vaccines for avian influenza	409
<i>Future prospects of DNA vaccines for avian influenza</i>	410
<i>Human trial of a DNA vaccine for avian influenza</i>	410
Companies developing genetic vaccines for infections other than AIDS	411
9. Research, Development and Future of Gene Therapy	413
Basic research in gene therapy	413
R & D in gene therapy	413
Animal models of human diseases for gene therapy research	414
<i>Lentiviral transgenesis</i>	414
Financing research and development	414
Role of the NIH in gene therapy research.....	414

National Gene Vector Laboratories	414
Funding of gene therapy research in Europe	415
<i>Gene therapy funding in Horizon 2020 of European Commission</i>	415
Financing by the industry	416
Clinical trials in gene therapy	416
Clinical trials worldwide	416
<i>Clinical trials in cancer gene therapy</i>	417
<i>Trials of gene therapy for neurological disorders</i>	417
<i>Clinical trials for genetic disorders</i>	417
<i>Clinical trials in cardiovascular gene therapy</i>	417
<i>Clinical trials for infectious diseases</i>	417
<i>Gene therapy for other disorders</i>	417
Clinical trials in the US	418
Vectors used in gene therapy clinical trials	418
<i>Vector analytics for clinical trials using rAAV vectors</i>	419
Future prospects for the gene therapy	419
How to improve gene therapy	420
International Gene Therapy Consortium	420
Future opportunities and challenges for gene therapy	422
Promising areas of application of gene therapy	422
<i>Neurological disorders</i>	423
<i>Gene therapy of cardiovascular disorders</i>	423
<i>Cancer gene therapy</i>	424
Personalized gene therapy	425
10. Regulatory, Safety, Ethical Patent Issues of Gene Therapy	427
Regulation of gene therapy in the United States	427
US Federal guidelines for research involving recombinant DNA molecules	427
Regulation of gene therapy in US	427
Implantation of genetically manipulated cells	427
<i>Modification of oocytes for use in IVF</i>	428
Clinical trials in gene therapy	428
Cell and gene therapy INDs placed on hold by the FDA	428
Regulation of gene therapy in Europe	429
European Union	429
Regulation of gene therapy in Germany	430
<i>Preclinical research</i>	430
<i>Clinical Trials</i>	431
Marketing authorization	432
Regulation of gene therapy in the United Kingdom	432
Regulation of gene therapy in France	433
Regulation of gene therapy in Italy	433
Regulation of gene therapy in the Netherlands	434
Gene therapy regulation in Switzerland	435
Regulation of gene therapy in Australia	435
Regulation of gene therapy in Japan	436
Regulation of gene therapy in China	436
Safety issues of gene transfer	437
Adverse effects of retroviral vectors	437
<i>Insertional mutagenesis</i>	437
Adverse effects of HSV vectors	438
<i>Neurotoxicity of HSV vectors</i>	438
<i>Hepatotoxicity of HSV-tk/ganciclovir approach</i>	438
Adverse effects of adenoviral vectors	439
<i>Inflammatory effects of adenoviruses in lungs</i>	439
<i>Inflammatory effects involving the liver</i>	439
<i>Induction of immune response by adenoviral vectors</i>	440
<i>Impairment of adrenocortical steroidogenesis</i>	440
<i>Adverse effects of AAV vectors</i>	440
Toxicity associated with cationic lipid-mediated gene transfer	441
Toxicity of lipopolysaccharides	441
Potential side effects of RNAi gene therapy	441
Role of molecular diagnostics in safety of gene therapy	442
Quality control of vectors	442
<i>Testing for retroviruses</i>	442
<i>Adenoviral vectors</i>	442
<i>Replication competent viruses</i>	443
Genetic characteristics of viral vectors	443
Concluding remarks about safety of viral vectors	443
Ethical aspects of gene therapy	444
The lay consumer's view of somatic gene therapy ethics	444

Ethical aspects of clinical trials.....	445
Regulatory and ethical issues for in utero gene therapy	445
Ethical aspects of germline gene therapy	445
Ethical aspects of mitochondrial replacement therapy	446
Ethical aspects of gene editing.....	446
<i>UNESCO's view on gene editing in humans</i>	447
<i>Gene editing in the UK</i>	447
<i>Gene editing in the US</i>	448
Germline gene therapy for genetic enhancement	449
Athletic enhancement by genetic engineering	449
<i>Gene doping in sports</i>	450
<i>Gene transfer methods used for enhancing physical performance</i>	450
<i>Adverse effect of genetic engineering</i>	452
<i>Problems in detecting genetic manipulations in athletes</i>	453
<i>Ethical dilemma</i>	453
Gene therapy patents	453
CRISP/Cas9 patents	454
11. Markets for Gene Therapy	457
Introduction	457
Gene therapy markets in various regions of the world.....	457
Gene therapy markets according to therapeutic areas.....	458
Cancer gene therapy market	458
Markets for gene therapy of genetic disorders	458
Markets for DNA vaccines	459
DNA vaccines markets according to technologies	459
DNA vaccines markets according to therapeutic indications	460
DNA vaccines markets according to geographical areas	460
Competing treatments	461
Antisense.....	461
RNAi.....	461
Cell therapy	461
Strategies for developing gene therapy markets	462
<i>Collaboration with pharmaceutical companies</i>	462
<i>Collaboration with companies developing cell-based therapies</i>	462
<i>Collaboration with academic gene therapy centers</i>	462
<i>Developing safer and cost-effective gene medicines</i>	462
<i>Intellectual property and commercialization of gene therapy</i>	462
<i>Overcoming obstructions to the development of gene therapy</i>	463
Unmet needs in gene therapy	463
Promises and challenges for the development of gene therapy	464
Development of gene therapy market in China	464
Challenges of developing gene therapy in the USA	465
Challenges of developing gene therapy in the European Union.....	465
12. References	467

Tables

Table 1-1: Landmarks in development of gene therapy.....	23
Table 2-1: Classification of methods of gene therapy.....	35
Table 2-2: A comparison of various physical methods of gene transfer	37
Table 2-3: Experimental applications of gene transfer by electroporation	38
Table 2-4: Companies developing CRISPR technology	55
Table 2-5: An overview of characteristics of commonly used viral vectors	58
Table 2-6: Companies using viral vectors.....	72
Table 2-7: Companies using nonviral vectors	91
Table 2-8: Target organs for nonviral gene therapy methods.	93
Table 2-9: Potential routes for administration of DNA	101
Table 2-10: Companies with gene delivery devices/ technologies.....	102
Table 2-11: Strategies for targeted gene therapy	104
Table 2-12: Animal experimental studies of in vivo gene delivery with polymer systems.....	105
Table 2-13: Approaches to controlling gene expression in gene therapy	106
Table 2-14: Companies with regulated/targeted gene therapy and special techniques	108
Table 2-15: Potential applications of human germline genome modification	110
Table 2-16: Applications of molecular diagnostics in gene therapy	123
Table 2-17: Advantages of gene therapy compared with protein therapy	126
Table 3-1: Experimental approaches to gene therapy of rheumatoid arthritis	131

Table 3-2: Gene therapy strategies for osteoarthritis.....	132
Table 3-3: Cell and gene therapy approaches for type 1 diabetes mellitus.....	139
Table 3-4: Indications for gastrointestinal gene therapy	146
Table 3-5: Hematological disorders that can be potentially treated by gene therapy.....	148
Table 3-6: Companies involved in gene therapy of hematological disorders.....	159
Table 3-7: Techniques of gene transfer to the kidneys.....	164
Table 3-8: Gene therapy in animal experimental models of renal disease.....	167
Table 3-9: Applications of gene therapy in ophthalmological disorders.....	175
Table 3-10: Companies developing gene therapy for eye disorders	191
Table 3-11: Strategies for gene delivery to the lungs	195
Table 3-12: Companies developing gene therapy for pulmonary disorders	204
Table 4-1: Genetic disorders that are being investigated for gene therapy	217
Table 4-2: X-linked immunodeficiency disorders	219
Table 4-3: Examples of inherited metabolic disorders amenable to gene therapy	224
Table 4-4: Gene therapy approaches to Duchenne muscular dystrophy	243
Table 4-5: Companies involved in gene therapy of genetic/metabolic disorders	258
Table 5-1: Strategies for cancer gene therapy	259
Table 5-2: Cell-based gene therapy for cancer	263
Table 5-3: Companies with nucleic acids/genetically modified cell cancer vaccines	271
Table 5-4: Enzyme/prodrug combinations employed in suicide gene therapy.....	275
Table 5-5: Mutation compensation strategies used clinically	276
Table 5-6: Companies developing oncolytic viruses	291
Table 5-7: Strategies for gene therapy of malignant brain tumors.....	294
Table 5-8: Clinical trials of oncolytic virotherapy against glioblastoma multiforme.....	301
Table 5-9: Clinical trials of gene therapy in ovarian cancer.....	303
Table 5-10: Gene therapy for malignant melanoma.....	304
Table 5-11: Clinical trials of gene therapy for prostate cancer	309
Table 5-12: Companies involved in cancer gene therapy.....	313
Table 6-1: Example of potential indications for gene therapy of neurologic disorder	317
Table 6-2: Methods of gene transfer as applied to neurologic disorders	318
Table 6-3: Gene therapy techniques applicable to Parkinson disease	324
Table 6-4: Companies developing gene therapy for Parkinson's disease.....	332
Table 6-5: Gene transfer in animal models of carotid artery restenosis.....	340
Table 6-6: Gene therapy strategies for vasospasm.....	341
Table 6-7: Neuroprotective gene therapy in animal stroke models	342
Table 6-8: Experimental gene therapy approaches for relief of pain	352
Table 6-9: Companies involved in gene therapy of neurological disorders	359
Table 7-1: Cardiovascular disorders that are potential indications for gene therapy.....	361
Table 7-2: Catheter-based systems for vector delivery to the cardiovascular system.....	362
Table 7-3: Companies involved in gene therapy of cardiovascular diseases	390
Table 8-1: Strategies for gene therapy of AIDS	394
Table 8-2: Companies involved in developing gene therapy for HIV/AIDS	405
Table 8-3: Companies developing genetic vaccines for infections other than AIDS	411
Table 9-1: Geographical distribution of gene therapy clinical trials	416
Table 9-2: Opportunities and challenges for gene therapy and resources needed.....	422
Table 9-3: Potential applications of gene therapy in disorders of the nervous system	423
Table 10-1: Genes that may be used for performance enhancement	451
Table 11-1: Gene therapy market according to regions/countries – 2016 to 2026	457
Table 11-2: Gene therapy markets according to therapeutic areas – 2016 to 2026.....	458
Table 11-3: Cancer gene therapy market according to type of cancer - 2016 to 2026.....	458
Table 11-4: Gene therapy market for selected genetic disorders - 2016 to 2026.....	459
Table 11-5: DNA vaccines markets according to technologies - 2016 to 2026.....	459
Table 11-6: DNA vaccines markets according to therapeutic indications - 2016 to 2026.....	460
Table 11-7: DNA vaccines markets according to geographical areas - 2016 to 2026.....	460

Figures

Figure 1-1: Relation of gene therapy to other biotechnologies	25
Figure 1-2: Relationship of DNA, RNA and protein in the cell	29
Figure 2-1: Ex vivo and in vivo techniques of gene therapy.....	36
Figure 2-2: Structure of the Helios gene gun.....	41
Figure 2-3: A scheme of CRISPR/Cas9 gene editing	48
Figure 2-4: Categories of rAAV-based gene therapy strategies	62
Figure 2-5: Bacteria plus nanoparticles for drug delivery into cells	89
Figure 2-6: Schematic of suppression of gene expression by RNAi	120
Figure 3-1: Retina and routes of administration of gene therapy for retinal disorders	181
Figure 4-1: Targeted gene correction of α 1-antitrypsin deficiency by iPSCs	227
Figure 4-2: Application of CRISPR-Cas9 in a mouse model of DMD.....	248
Figure 4-3: Techniques for mitochondrial nuclear transfer.....	256
Figure 5-1: Chimeric antigen receptor (CAR)-T cells attacking tumor cells.....	281

Figure 5-2: Gene therapy approaches for pancreatic cancer	310
Figure 6-1: Effect of tyrosine hydroxylase gene delivery on dopamine levels	325
Figure 6-2: Role of cell and gene therapy in stroke according to pathology and stage.....	345
Figure 9-1: Product development cycle in gene therapy	413
Figure 9-2: Proportions of therapeutic areas in clinical trials of gene therapy in the US.....	418
Figure 9-3: Proportions of various vectors used in gene therapy trials	418
Figure 10-1: Evaluation system of gene therapy clinical studies in Japan	436
Figure 11-1: Unmet needs in gene therapy	464